Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026

Stanley Druckenmiller's Duquesne Family Office has significantly reduced its exposure to leading AI stocks, liquidating all Nvidia shares and cutting Palantir by 95%, citing extreme valuations (Nvidia P/S >40, Palantir P/S 73) and concerns over a potential tech bubble after their substantial year-to-date gains. Concurrently, Druckenmiller significantly increased his stake in Teva Pharmaceutical Industries, betting on its turnaround driven by resolved opioid litigation, a strategic shift to higher-margin brand-name drugs, a promising pipeline with positive Phase 2b data for duvakitug, and substantial debt reduction, positioning it as an undervalued opportunity.

Analysis

Stanley Druckenmiller's Duquesne Family Office significantly reduced its exposure to prominent AI stocks, liquidating all 6,174,940 Nvidia shares and cutting its Palantir Technologies stake by 95% (728,255 shares) by September 30. This divestment follows substantial year-to-date gains (NVDA +172%, PLTR +369%), suggesting profit-taking, but also reflects concerns over potential market exuberance.

The article highlights a historical pattern of "next-big-thing" innovations experiencing hype cycles followed by corrections, suggesting AI could be Wall Street's next bubble. Nvidia's trailing-12-month price-to-sales (P/S) ratio surpassed 40, comparable to dot-com bubble peaks, while Palantir's P/S ratio reached an all-time high of 73, implying likely retracements.

Concurrently, Druckenmiller significantly increased his position in Teva Pharmaceutical Industries, adding 1,427,950 shares, with the stock up 112% year-to-date. This investment is predicated on Teva's successful turnaround, marked by the resolution of opioid litigation ($4.25 billion settlement) and a strategic shift to higher-margin brand-name therapies, with Austedo and Ajovy sales growing over 20% in Q3.

Teva's financial health has improved substantially, reducing net debt from over $35 billion to less than $15.7 billion. Its pipeline shows promise, particularly with positive Phase 2b data for duvakitug, an IBD treatment with potential peak annual sales exceeding $1 billion, making its valuation of less than 8 times forecast 2025 EPS compelling.

Key Decisions for Investors

• Investors should critically re-evaluate exposure to high-valuation AI stocks like Nvidia and Palantir, considering potential profit-taking and historical patterns of tech bubbles.
• Scrutinize current price-to-sales multiples for AI holdings, as levels like Palantir's 73x TTM P/S may not be sustainable.
• Consider opportunities in companies undergoing fundamental turnarounds, such as Teva Pharmaceutical, which has resolved significant litigation, improved financials, and shifted to higher-margin products.
• Evaluate diversifying portfolios into sectors with improving fundamentals and more reasonable valuations, as demonstrated by Druckenmiller's strategic shift.